South Korean biopharmaceutical company Celltrion Inc. announced on Wednesday that it has obtained product approval from the US Food and Drug Administration for its biosimilar of the autoimmune disease treatment drug Humira (adalimumab) called CT-P17 (brand name: Yuflyma).As a result, Celltrion
Celltrion's Remsima South Korean biopharmaceutical company Celltrion Healthcare Co. revealed on Monday its introduction of Remsima SC, a treatment for autoimmune diseases, in Brazil, the largest pharmaceutical market in Latin America. The company received approval from the Brazilian Health
Samsung Biologics headquarters in Incheon, South Korea (Courtesy of Samsung Biologics) Samsung Biologics Co. is slated to inject 1 trillion won ($762.2 million) to build its fifth plant in South Korea. It will be a fast follow-up investment as the construction of its fourth plant, the world's l
Samsung Biologics Co., the world’s top contract drugmaker, said its profit almost doubled last year thanks to more orders as its sales surged after acquiring a nearly 50% stake in a biosimilar joint venture with Biogen Inc.Samsung Biologics on Friday reported an operating profit of 983.6
Lotte Group Chairman Shin Dong-bin presides over a CEO meeting South Korea's Lotte Group has agreed to buy Bristol Myers Squibb's (BMS) biologics plant in Syracuse in the state of New York for $160 million, the group said on Friday, taking its first significant step toward the bio industr